Topotecan in the Treatment of Acquired Immunodeficiency Syndrome-Related Progressive Multifocal Leukoencephalopathy

References

• Barnett AA (1996). FDA approve bark-derived drug. Lancet 347: 1613.
   PubMedGoogle Scholar
• Berger JR (2000). Progressive multifocal leukoencephalopa-thy. Curr Treat Options Neurol 2: 361–368.
   PubMedGoogle Scholar
• Berger JR, Kaszovitz B, et al (1987). Progressive multifocal leukoencephalopathy associated with human immun-odeficiency virus infection. A review of the literature with a report of sixteen cases. Ann Intern Med 107: 78–87.
   Google Scholar
• Berger JR, Major EO (1999). Progressive multifocal leukoen-cephalopathy. Semin Neurol 19: 193–200.
   PubMed Web of Science ®Google Scholar
• Brambilla AM, Castagna A, et al (1999). Remission of AIDS-associated progressive multifocal leukoencephalopathy after cidofovir therapy. J Neurol 246: 723–725.
   PubMed Web of Science ®Google Scholar
• Brown P, Tsai T, et al (1975). Seroepidemiology of hu-man papovaviruses. Discovery of virgin populations and some unusual patterns of antibody prevalence among remote peoples of the world. Am J Epidemiol 102: 331–340.
   Google Scholar
• Chang L, Ernst T, et al (1997). Metabolite abnormalities in progressive multifocal leukoencephalopathy by proton magnetic resonance spectroscopy. Neurology 48: 836–845.
   Google Scholar
• Clifford DB, Yiannoutsos C, et al (1999). HAART im-proves prognosis in HIV-associated progressive multi-focal leukoencephalopathy. Neurology 52: 623–625.
   PubMed Web of Science ®Google Scholar
• De Luca A, Giancola ML, et al (2000). Cidofovir added to HAART improves virological and clinical outcome in AIDS-associated progressive multifocal leukoen-cephalopathy. AIDS 14: F117–F121.
   Google Scholar
• Dore GJ, Correll PK, et al (1999). Changes to AIDS demen-tia complex in the era of highly active antiretroviral ther-apy. AIDS 13: 1249–1253.
   PubMed Web of Science ®Google Scholar
• Dworkin MS, Wan PC, et al (1999). Progressive multifocal leukoencephalopathy: improved survival of human im-munodeficiency virus-infected patients in the protease inhibitor era. J Infect Dis 180: 621–625.
   PubMed Web of Science ®Google Scholar
• Enting RH, Portegies P (2000). Cytarabine and highly active antiretroviral therapy in HIV-related progressive multi-focal leukoencephalopathy. J Neurol 247: 134–138.
   Google Scholar
• Ernst T, Chang L, et al (1999). Progressive multifocal leukoencephalopathy and human immunodeficiency virus-associated white matter lesions in AIDS: magne-tization transfer MR imaging. Radiology 210: 539–543.
   Google Scholar
• Evans RH, Scadden DT (2000). Haematological aspects of HIV infection. Baillieres Best Bract Res Clin Haematol 13: 215–230.
   PubMed Web of Science ®Google Scholar
• Fong IW, Toma E (1995). The natural history of progressive multifocal leukoencephalopathy in patients with AIDS. Canadian PML Study Group. Clin Infect Dis 20: 1305–1310.
   PubMed Web of Science ®Google Scholar
• Gasnault J, Kousignian P, et al (2001). Cidofovir in AIDS-associated progressive multifocal leukoencephalopathy: a monocenter observational study with clinical and JC virus load monitoring. J Neurovirol 7: 375–381.
   PubMed Web of Science ®Google Scholar
• Gasnault J, Taoufik Y, et al (1999). Prolonged survival with-out neurological improvement in patients with AIDS-related progressive multifocal leukoencephalopathy on potent combined antiretroviral therapy. J Neurovirol 5: 421–429.
   PubMed Web of Science ®Google Scholar
• Geschwind MD, Skolasky RI, et al (2001). The relative con-tributions of HAART and alpha-interferon for therapy of progressive multifocal leukoencephalopathy in AIDS. J NeuroVirol 7: 353–357.
   PubMed Web of Science ®Google Scholar
• Hochster H, Liebes L, et al (1994). Phase I trial of low-dose continuous topotecan infusion in patients with cancer:an active and well-tolerated regimen. J Clin Oncol 12: 553–559.
   PubMed Web of Science ®Google Scholar
• Huang SS, Skolasky RL, et al (1998). Survival prolonga-tion in HIV-associated progressive multifocal leukoen-cephalopathy treated with alpha-interferon: an observa-tional study. J Neurovirol 4: 324–332.
   PubMed Web of Science ®Google Scholar
• Itti L, Chang L, et al (2001). Segmentation of progres-sive multifocal leukoencephalopathy lesions in fluid-attenuated inversion recovery magnetic resonance imag-ing. J Neuroimaging 11: 412–417.
   Google Scholar
• Kerr DA, Chang CF, et al (1993). Inhibition of human neu-rotropic virus (JCV) DNA replication in glial cells by camptothecin. Virology 196: 612–618.
   PubMed Web of Science ®Google Scholar
• Li CJ, Zhang LJ, et al (1993). Three inhibitors of type 1 human immunodeficiency virus long terminal repeat-directed gene expression and virus replication. Proc Natl Acad Sci USA 90: 1839–1842.
   PubMed Web of Science ®Google Scholar
• Major EO, Amemiya K, et al (1992). Pathogenesis and molecular biology of progressive multifocal leukoen-cephalopathy, the JC virus-induced demyelinating dis-ease of the human brain. Clin Microbic)] Rev 5: 49–73.
   PubMed Web of Science ®Google Scholar
• Moore RD, Chaisson RE (1999). Natural history of HIV in-fection in the era of combination antiretroviral therapy. AIDS 13: 1933–1942.
   PubMed Web of Science ®Google Scholar
• Nicoli F, Chave B, et al (1992). Efficacy of cytarabine in progressive multifocal leucoencephalopathy in AIDS. Lancet 339: 306.
   Google Scholar
• Portegies P, Algra PR, et al (1991). Response to cytarabine in progressive multifocal leucoencephalopathy in AIDS. Lancet 337: 680–681.
   PubMed Web of Science ®Google Scholar
• Sacktor N, Lyles RH, et al (2001). HIV-associated neuro-logic disease incidence changes: Multicenter AIDS Co-hort Study, 1990–1998. Neurology 56: 257–260.
   Google Scholar
• Sausville EA, Horwitz SB (1978). Inhibition of 5V40 DNA synthesis by camptothecin and neocarzinostatin. Mol Pharmaco114: 1156–1166.
   Google Scholar
• Tantisiriwat W, Tebas P, et al (1999). Progressive multifocal leukoencephalopathy in patients with AIDS receiving highly active antiretroviral therapy. Clin Infect Dis 28: 1152–1154.
   PubMedGoogle Scholar
• Taoufik Y, Delfraissy JF, et al (2000). Highly active an-tiretroviral therapy does not improve survival of patients with high JC virus load in the cerebrospinal fluid at progressive multifocal leukoencephalopathy diagnosis. AIDS 14: 758–759.
   PubMed Web of Science ®Google Scholar
• Weiner SM, Laubenberger J, et al (2000). Fatal course of HIV-associated progressive multifocal leukoen-cephalopathy despite successful highly active antiretro-viral therapy. /infect 40: 100–102.
   Google Scholar
• Yang L, Wold MS, et al (1987). Roles of DNA topoiso-merases in simian virus 40 DNA replication in vitro. Proc Nati Acad Sci USA 84: 950–954.
   PubMed Web of Science ®Google Scholar
• Yiannoutsos CT, De Luca A (2001). Designs for clinical tri-als to test the efficacy of therapeutics in progressive mul-tifocal leukoencephalopathy. J NeuroVirol 7: 369–374.
   Google Scholar
• Zhang JL, Sharma PL, et al (1997). Topotecan inhibits hu-man immunodeficiency virus type 1 infection through a topoisomerase-independent mechanism in a cell line with altered topoisomerase I. Antimicrob Agents Chemother 41: 977–981.
   Google Scholar